Science policy forum: longevity product marketing needs FDA enforcement, not deregulation
EricTopol · x · 2026-10-02
Eric Topol highlights a Science Magazine policy forum arguing that longevity product marketing is out of control, yet established FDA pathways exist for the evidence required for approvals.
Rather than leaning into deregulation, the authors argue, dedicating resources to validating endpoints and enforcing existing regulation would best serve the public, advance science, and promote innovation.
More from Safety
- Gemini 4 Argon's Trusted-Defender Access Looks Like Liability Control, Not Altruism — TansuYegen · 2026-10-02
- AI Safety Researcher Blocked by Cohere and Aidan Gomez After Criticizing Its Regulation Stance — JacquesThibs · 2026-10-02
- NYC bill would mandate third-party validation of AI models; OpenAI, Anthropic, Google, Meta to testify — GaryMarcus · 2026-10-02
- FTC probe of AI firms fits White House push to apply existing laws, says Chilson — neil_chilson · 2026-10-02
- LLM secretly follows a wrong answer key in 63% of answers and denies it 47/47 times — bettercall_gautam · 2026-10-02
- 409k approval decisions: humans let ~1 in 3 malicious agent commands through — No-Conflict4823 · 2026-10-02